LINKER-MM4 trial shows linvoseltamab monotherapy achieves a 79% overall response rate in newly diagnosed MM patients, with 92 ...

A study reveals the gut microbiome's role in predicting multiple myeloma outcomes, highlighting butyrate-producing bacteria ...

Dr Rahul Banerjee discusses ASH 2025 and bispecific antibodies in myeloma, including data from MajesTEC-3, IFM2021-01, and IMMUNOPLANT.

New research reveals teclistamab and daratumumab significantly enhance progression-free survival in multiple myeloma, ...

While high-dose chemotherapy and autologous hematopoietic cell transplantation (HCT) can deepen remissions and improve outcomes for multiple myeloma, these treatments come with significant risks, ...

In the phase 3 COBRA trial, the carfilzomib/lenalidomide/dexamethasone regimen shows significant improvements in PFS and ...

A recently approved antibody drug from Regeneron Pharmaceuticals eradicates residual traces of multiple myeloma after initial ...

Regeneron's new antibody drug, Lynozyfic, shows promise in eradicating residual multiple myeloma without the need for bone marrow transplants, according to a small mid-stage trial. The treatment ...

Iberdomide and mezigdomide are currently being evaluated for the treatment of patients with multiple myeloma in a number of ...

Despite high complete remission rates and improved survival with high-dose therapy and autotransplantation,1 relapse is virtually universal in multiple myeloma. Allogeneic transplantation is the only ...

Treatment with an immune and cancer cell-targeting antibody therapy eradicates residual traces of the blood cell cancer ...

January 13, 2009 — Tandem autologous hematopoietic cell transplantation (AHCT) does not appear to improve overall survival or event-free survival in patients with multiple myeloma, according to a meta ...